title: Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules.
abstract: BACKGROUND
  In 2001 when 7-valent pneumococcal conjugate vaccine (PCV7) was introduced, almost all (90%) young Australian Indigenous children living in remote communities had some form of otitis media (OM), including 24% with tympanic membrane perforation (TMP). In late 2009, the Northern Territory childhood vaccination schedule replaced PCV7 with 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10).
  
  
  METHODS
  We conducted regular surveillance of all forms of OM in children in remote Indigenous communities between September 2008 and December 2012. This analysis compares children less than 36 months of age who received a primary course of at least two doses of PCV7 or PHiD-CV10, and not more than one dose of another pneumococcal vaccine.
  
  
  RESULTS
  Mean ages of 444 PCV7- and 451 PHiD-CV10-vaccinated children were 20 and 18 months, respectively. Bilaterally normal middle ears were detected in 7% and 9% respectively. OM with effusion was diagnosed in 41% and 51% (Risk Difference 10% [95% Confidence Interval 3 to 17] p = 0.002), any suppurative OM (acute OM or any TMP) in 51% versus 39% (RD -12% [95% CI -19 to -5] p = 0.0004], and TMP in 17% versus 14% (RD -3% [95% CI -8 to 2] p = 0.2), respectively. Multivariate analyses described a similar independent negative association between suppurative OM and PHiD-CV10 compared to PCV7 (Odds Ratio = 0.6 [95% CI 0.4 to 0.8] p = 0.001). Additional children in the household were a risk factor for OM (OR = 2.4 [95% CI 2 to 4] p = 0.001 for the third additional child), and older age and male gender were associated with less disease. Other measured risk factors were non-significant. Similar clinical results were found for children who had received non-mixed PCV schedules.
  
  
  CONCLUSIONS
  Otitis media remains a significant health and social issue for Australian Indigenous children despite PCV vaccination. Around 90% of young children have some form of OM. Children vaccinated in with PHiD-CV10 had less suppurative OM than children vaccinated with PCV7. Ongoing surveillance during the PCV13 era, and trials of early intervention including earlier and mixed vaccine schedules are warranted.
authors.affiliation: Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia. Amanda.leach@menzies.edu.au.
authors.forename: Amanda Jane
authors.initials: AJ
authors.lastname: Leach
authors.forename: Christine
authors.initials: C
authors.lastname: Wigger
authors.forename: Ross
authors.initials: R
authors.lastname: Andrews
authors.forename: Mark
authors.initials: M
authors.lastname: Chatfield
authors.forename: Heidi
authors.initials: H
authors.lastname: Smith-Vaughan
authors.forename: Peter Stanley
authors.initials: PS
authors.lastname: Morris
mesh_terms: D001315:Australia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D016015:Logistic Models; D008297:Male; D032541:Mass Vaccination; D015999:Multivariate Analysis; D010033:Otitis Media / Q000150:complications / Q000208:ethnology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D015995:Prevalence; D062486:Public Health Surveillance; D012307:Risk Factors; D016896:Treatment Outcome; D018058:Tympanic Membrane Perforation / Q000208:ethnology / Q000209:etiology / Q000517:prevention & control; D018074:Vaccines, Conjugate
chemical_list: C586648:10-valent pneumococcal conjugate vaccine; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
references.citation: Clin Infect Dis. 2013 Feb;56(3):e30-9
references.pmid: 23118268
references.citation: PLoS Med. 2011 Oct;8(10):e1001107
references.pmid: 22028630
references.citation: Vaccine. 2007 Mar 22;25(13):2389-93
references.pmid: 17030497
references.citation: Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004401
references.pmid: 17054203
references.citation: Pediatr Infect Dis J. 2013 Jul;32(7):709-14
references.pmid: 23411622
references.citation: Eur J Pediatr. 1999 Jan;158(1):1-6
references.pmid: 9950299
references.citation: BMC Pediatr. 2008 Jun 02;8:23
references.pmid: 18513453
references.citation: Pediatr Infect Dis J. 2007 Oct;26(10 Suppl):S4-7
references.pmid: 18049380
references.citation: BMC Pediatr. 2005 Jul 20;5:27
references.pmid: 16033643
references.citation: BMC Ear Nose Throat Disord. 2013 Oct 08;13(1):12
references.pmid: 24099576
references.citation: Med J Aust. 2010 Jan 4;192(1):24-9
references.pmid: 20047544
references.citation: BMC Infect Dis. 2009 Aug 04;9:121
references.pmid: 19650933
references.citation: Med J Aust. 2011 Feb 7;194(3):116-20
references.pmid: 21299484
references.citation: Lancet. 2006 Mar 4;367(9512):740-8
references.pmid: 16517274
references.citation: Pediatr Infect Dis J. 2011 Jun;30(6):480-5
references.pmid: 21593705